KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Operating Expenses (2016 - 2026)

AbbVie has reported Operating Expenses over the past 14 years, most recently at $12.1 billion for Q4 2025.

  • Quarterly Operating Expenses fell 27.23% to $12.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.1 billion through Dec 2025, down 2.36% year-over-year, with the annual reading at $46.1 billion for FY2025, 2.36% down from the prior year.
  • Operating Expenses was $12.1 billion for Q4 2025 at AbbVie, down from $13.9 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $16.6 billion in Q4 2024 and troughed at $8.8 billion in Q1 2022.
  • The 5-year median for Operating Expenses is $10.1 billion (2021), against an average of $10.7 billion.
  • Year-over-year, Operating Expenses soared 77.57% in 2021 and then fell 27.23% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $9.8 billion in 2021, then dropped by 1.97% to $9.6 billion in 2022, then rose by 15.46% to $11.1 billion in 2023, then surged by 49.4% to $16.6 billion in 2024, then dropped by 27.23% to $12.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Operating Expenses are $12.1 billion (Q4 2025), $13.9 billion (Q3 2025), and $10.5 billion (Q2 2025).